Cell and Gene Outsourcing

1. Oncology Clinical Trial Excellence Delivered Worldwide 10/23/2026

   Cancer trials stall when start-up drags, or teams turn over. See how site ties, steady teams, and early data insights keep oncology studies on track.

2. Bringing Hematologic Oncology Therapies To Cancer Patients 10/23/2026

   Blood cancer trials bring complex protocols, shifting care standards, and tough enrollment. Learn how specialized expertise helps sponsors move therapies from first study to approval faster.

3. From Laboratory To Launchpad: Japan's Cell And Gene Therapy Ecosystem Hits Its Stride 10/21/2026

   Japan is emerging as a credible cell and gene therapy hub as regulation, manufacturing, and capital advance, despite gaps in funding, talent, risk culture, and language.

4. Choosing A CDMO That Can Grow With A Viral Program 10/21/2026

   Viral modalities demand more from CDMO selection: relevant experience, rigorous tech transfer, analytical readiness, and a clear path to scale matter more than equipment alone.

5. RNA Whole Transcriptome Sequencing From Challenging Matrices: Insights From Tissue 10/20/2026

   RNA extraction from skin, gut, and tumor biopsies demands a systematic approach, from sample preservation through porcine method development to human validation, with direct consequences for sequencing performance.

6. Connected By Design: Laboratory Automation And Digital Transformation Strategy 10/19/2026

   Task-level automation delivers isolated gains, but the larger payoff in GxP laboratories comes from connecting instruments, systems, and data into workflows where samples move with minimal human handoffs.

7. Precision At Scale: Optimizing Cell-Free DNA Manufacturing For mRNA Vaccines 10/16/2026

   Backbone-free enzymatic DNA templates can improve polyA integrity, long-transcript quality, and RNA yield, with implications for IVT timelines and regulation.

8. Uncovering The Potential Of Exosomes 10/16/2026

   Exosomes show early promise as drugs and drug carriers, but limited understanding of how their characteristics relate to function complicates isolating specific populations and scaling production.

9. Need To Accelerate Your In Vivo CAR-T? You Need Lonza. 10/16/2026

   In vivo CAR-T and gene editing recast cell therapy as a delivery problem. Lentiviral and RNA-LNP routes each need scalable, well-characterized, regulatory-ready candidates, with quality built in early.

10. Cell & Gene Therapy - End To End Services 10/16/2026

    Cell and gene therapy development works best when process, manufacturing, analytical and regulatory planning start together, across modalities from autologous cell therapy to viral vectors, in vivo applications and vesicles.